VolitionRX Limited (NYSEAMERICAN:VNRX) Sees Large Growth in Short Interest

Key Points

• Short interest in VolitionRX Limited surged by 67.7% in August, reaching a total of 298,500 shares as of August 31st.
• The stock is currently trading at $0.63, which is a decline of 3.9% from previous trading sessions, with a market capitalization of $67.81 million.
• VolitionRX is a multi-national epigenetics company focused on developing blood tests for diagnosing and monitoring various cancers, as well as other health conditions like sepsis and COVID-19.

VolitionRX Limited (NYSEAMERICAN:VNRX - Get Free Report) saw a large increase in short interest in August. As of August 31st, there was short interest totaling 298,500 shares, an increase of 67.7% from the August 15th total of 178,000 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average trading volume of 224,700 shares, the days-to-cover ratio is currently 1.3 days. Based on an average trading volume of 224,700 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.3% of the shares of the company are short sold.

VolitionRX Price Performance

Shares of NYSEAMERICAN VNRX traded up $0.06 during midday trading on Friday, hitting $0.68. 501,831 shares of the company's stock were exchanged, compared to its average volume of 187,943. The stock's 50 day moving average price is $0.67 and its 200-day moving average price is $0.60. The firm has a market cap of $73.17 million, a P/E ratio of -2.72 and a beta of 1.27. VolitionRX has a twelve month low of $0.40 and a twelve month high of $0.94.

About VolitionRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.